Pulmonary Fibrosis Regulation by miR-1

Information

  • Research Project
  • 10256727
  • ApplicationId
    10256727
  • Core Project Number
    U54MD015929
  • Full Project Number
    5U54MD015929-02
  • Serial Number
    015929
  • FOA Number
    RFA-MD-20-006
  • Sub Project Id
    6611
  • Project Start Date
    9/8/2020 - 3 years ago
  • Project End Date
    5/31/2025 - 10 months from now
  • Program Officer Name
  • Budget Start Date
    6/1/2021 - 3 years ago
  • Budget End Date
    5/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    5/5/2021 - 3 years ago
Organizations

Pulmonary Fibrosis Regulation by miR-1

Summary/Abstract: Fibrotic diseases are associated with high morbidity and mortality. Pulmonary fibrosis (PF) is a progressive disease with no effective treatment except lung transplant. PH is also a risk factor for other health complications including lung cancer. A major characteristic of PF is increased deposition of extracellular matrix (ECM) that leads to lung tissue stiffening and loss of function. PF is a heterogeneous disease characterized by aberrant signaling pathways of oxidative stress (OS), TGF?, and NF-?B. We have previously reported increased ROS and activation of MAPK, NF-?B, and TGF? in alveolar epithelial cells following treatment with known lung fibrotic toxicants silica and multi-walled carbon nanoparticles (MWCNT). Our previous studies also showed increased expression of Col3A1 and TGF? in alveolar epithelial cells in response to MWCNT. While PF is multifactorial, studies have linked reactive oxygen species (ROS) and aberrant microRNAs (miRs) in lung fibrosis development. How exactly ROS regulate miRs that drive lung fibrosis development remains largely unknown and is the focus of the present application. In our study of human alveolar epithelial (A549) cells exposed to MWCNT, we found that: (1) miR-1 is downregulated; (2) TSP-1 is up-regulated; and (3) exogenous mimic miR-1 suppresses TSP-1, a major activator of TGF?. These findings suggest that miR-1 and TSP-1 are regulated by MWCNT and targeting miR-1 and TSP-1 might inhibit TGF?-mediated fibrotic response. The central hypothesis of the current project is that ROS suppress miR-1 which promotes increased TSP-1 and active TGF? fibrotic signaling. Specific aims are: (1) determine the mechansims by which miR-1 is regulated; (2) determine the mechanistic link between miR-1 and fibrotic signaling via TSP-1/TGF? (or other pathways emerging from mRNASeq data); and (3) determine the function of miR-1 in lung fibrosis in vivo by analyzing whether a model of bleomycin- and MWCNT-lung fibrosis in mice and exogenous miR-1 treated mice are less prone to lung fibrosis than control miR-1 untreated mice. The proposed study will elucidate cellular and molecular mechanism involved in lung fibrosis by targeting TSP-1 via miR-1. This hypothesis, if proven, will establish a potential microRNA therapy in pulmonary fibrosis.

IC Name
National Institute on Minority Health and Health Disparities
  • Activity
    U54
  • Administering IC
    MD
  • Application Type
    5
  • Direct Cost Amount
    112480
  • Indirect Cost Amount
    54815
  • Total Cost
  • Sub Project Total Cost
    167295
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIMHD:167295\
  • Funding Mechanism
    RESEARCH CENTERS
  • Study Section
    ZMD1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    JACKSON STATE UNIVERSITY
  • Organization Department
  • Organization DUNS
    044507085
  • Organization City
    JACKSON
  • Organization State
    MS
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    392170001
  • Organization District
    UNITED STATES